News Posts List
Thyroid dysfunction in patients with advanced RCC
03/01/2012
Several studies have reported the substantial prevalence of sunitinib-induced thyroid dysfunction.
Long-term safety of sorafenib
03/01/2012
A retrospective subgroup analysis was performed to evaluate the efficacy and safety of sorafenib in patients in TARGET who received treatment for >1year.
FDA approves Inlyta for advanced kidney cancer
02/29/2012
The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.
Role of lymph node dissection in RCC
02/29/2012
Controversy exists over whether lymph node dissection (LND) simply provides improved staging or whether removal of pathologic nodes offers a therapeutic advantage.
Axitinib Tops Sorafenib as Second-Line RCC Treatment
02/29/2012
Axitinib treatment led to a significant and clinically meaningful improvement in progression-free survival compared with sorafenib in patients with treatment-refractory renal-cell carcinoma...
Study: Bevacizumab in Combination With Low-Dose-Interferon
02/28/2012
This single arm study will assess progression free survival, tumor response and safety of Avastin in combination with interferon alfa-2a (IFN) as first line treatment in patients with metastatic clear cell renal cell carcinoma.
Pre-Surgical Sutent in Renal Cell Carcinoma
02/24/2012
The goal of this clinical research study is to learn if Sutent® (sunitinib malate), given before surgery, can help control renal cell carcinoma. The safety of sunitinib malate will also be studied.
IL-7 Treating Patients With Metastatic Kidney Cancer
02/24/2012
This phase I trial is studying the side effects and best dose of interleukin-7 in treating patients with metastatic melanoma or locally advanced or metastatic kidney cancer.
News Feed